Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease?
Multiple sclerosis is an inflammatory disease of the CNS and a leading cause of disability. Inflammatory mediators play an orchestrating part in lesional development leading to symptoms. Chemokines -- chemoattractant cytokines -- regulate the inflammatory composite of the MS lesion. This review focuses on the present data regarding CXCL10 (previously known as IP-10) and CXRC3 in multiple sclerosis, since consistent data has suggested that this chemokine/chemokine receptor pair has a pivotal role in leukocyte recruitment into the central nervous system (CNS) in multiple sclerosis.
Sorensen
Torben Lykke
TL
The MS Clinic, Department of Neurology, University of Copenhagen, Glostrup Hospital, Denmark. torbenls@dadlnet.dk
D000818:Animals; D002490:Central Nervous System / Q000378:metabolism*; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism*; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000378:metabolism*
C515187:CXCR3 protein, human; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D008024:Ligands; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine